Speaker Profile
Biography
Lisa Gurry is the Chief Business Officer at GeneDx, where she is leading the company through its next phase of growth advancing data and information services across biopharma, health systems, and other partners to accelerate the future of precision medicine. In this role, Lisa drives GeneDxs strategic business operations and partnership models, unlocking the full potential of GeneDx Infinity, the largest rare disease dataset. She also oversees the companys communications function and collaborates on market growth strategies. With deep expertise at the intersection of healthcare, technology, and data, Lisa has a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, serving as Chief Growth Officer, Chief Marketing Officer, and Chief Operating Officer. She built the growth engine that helped secure strategic partnerships with more than 100 organizations across life sciences, healthcare, public health, and academic research. Earlier in her career, Lisa spent more than two decades at Microsoft, leading global teams and driving global growth strategies, marketing, and communications for Windows, Office, and Xbox. Lisa has a BA in communications from University of Arkansas, where she ran cross country and track. Lisa also has a daughter with several rare diseases, which culminated in a 13-year diagnostic odyssey. She is passionate about helping patients and families receive answers to transform lives.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
Gad Getz, Broad Institute
Alex Morgan, Khosla Ventures
PMWC Award Ceremony Honoree
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Keynote
• Vinod Khosla, Khosla Ventures
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Illuminating Drug Discovery: AI Models That Learn From Biology
• Erwin Estigarribia, HEADLAMP Health
Harmonizing the Data Economy: Enabling AI Across Institutions and Therapeutic Areas
• Noah Nasser, Datma
Can AI Really Create the Next Blockbuster Drug?
• James Zou, Stanford
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
Closing the Loop: AI in the Messy Middle of Drug Development
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald / MIT
Is AI the New Drug?
• Michael J. Kahana, Nia Therapeutics




